Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as CTX-009
Tovecimig · 4 trials · 9 indications
Percentage of patients whose Best Overall Response (BOR) is assessed as Complete Response (CR) or Partial Response (PR). Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by CT or MRI: CR: disappearance of all target lesions; PR: \>=30% decrease in the sum of the longest diameter of target lesions.
Defined as the proportion of patients who have a partial response (PR) or complete response (CR) per RECIST 1.1. CR is defined as disappearance of all target lesions and disappearance of all non-target lesions and normalization of tumor marker level. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.
Percentage of patients whose best overall response is assessed as complete response (CR) or partial response (PR). Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by CT or MRI: CR: disappearance of all target lesions; PR: \>=30% decrease in the sum of the longest diameter of target lesions.
Adverse events will be graded according to CTCAE v6.0
RP2D will be determined from the phase IB portion of Arm 1 by assessing tolerability. Tolerability is defined as ≤1 among patients experiencing excessive dose limiting toxicities (DLTs). The dose level in phase IB determined to be tolerable is the RP2D.
Adverse events will be graded according to CTCAE v6.0
Overall survival is defined from time of treatment start to time of death due to any cause or latest follow-up, whichever is earlier, with an inference focus on 12-month overall survival.
Overall survival is defined from time of treatment start to time of death due to any cause or latest follow-up, whichever is earlier, with an inference focus on 12-month overall survival.
| Arm | Type | Description |
|---|---|---|
| CTX-009 plus Paclitaxel | EXPERIMENTAL | - |
| Paclitaxel | ACTIVE_COMPARATOR | Patients randomized to receive paclitaxel only have the option to crossover to the CTX-009 plus paclitaxel arm after documented disease progression per RECIST v1.1. |
| Tovecimig and Irinotecan + Leucovorin + 5-Fluorouracil (FOLFIRI regimen) | EXPERIMENTAL | Treatment will be administered in 28-day cycles. On Day 1 and 15 of each cycle, patients will receive Tovecimig followed by the FOLFIRI regimen. |
| CTX-009 Treatment | EXPERIMENTAL | - |
| Phase IB Arm 1: CTX-009 monotherapy | EXPERIMENTAL | CTX-009 will be given intravenously at the assigned dose level on an outpatient basis every 2 weeks of a 28-day cycle. |
| Phase IB Arm 2: CTX-009 and CTX-471 combination therapy | EXPERIMENTAL | CTX-009 will be given intravenously at the dose determined to be the recommended phase II dose (RP2D) in Arm 1 every 2 weeks, and CTX-471 will be given intravenously at a dose of 0.3 mg/kg every 2 weeks (day 1 and day 15). On days when both drugs are given, CTX-009 will be given first, followed by a 30-minute observation period, followed by CTX-471. Cycles will be 28 days. |
| Phase II Expansion Arm 1: CTX-009 monotherapy | EXPERIMENTAL | CTX-009 will be given intravenously at the recommended phase 2 dose (RP2D) determined from Phase IB on an outpatient basis every 2 weeks of a 28-day cycle. |
| Phase II Expansion Arm 2: CTX-009 and CTX-471 combination therapy | EXPERIMENTAL | CTX-009 will be given intravenously at the dose determined to be the recommended phase II dose (RP2D) every 2 weeks (day 1 and day 15). CTX-471 will be given intravenously at a dose of 0.3 mg/kg every 2 weeks (day 1 and day 15). On days when both drugs are given, CTX-009 will be given first, followed by a 30-minute observation period, followed by CTX-471. Cycles will be 28 days. |
| Name | Type | Description |
|---|---|---|
| CTX-009 | DRUG | IV infusion on day 1 and 14 of every 28 day cycle |
| Paclitaxel | DRUG | IV infusion on day 1, 8, and 15 of every 28 day cycle |
| Tovecimig | BIOLOGICAL | Tovecimig is provided in 10 mg/kg dose intravenously over the course of 60 minutes on Day 1 and Day 15 of a 28-day cycle. |
| Irinotecan | DRUG | Standard of care irinotecan will be given at a dose of 180 mg/m\^2 intravenously on Day 1 and Day 15 of each 28-day cycle as part of the FOLFIRI treatment regimen. |
| Leucovorin | DRUG | Standard of care leucovorin will be given at a dose of 400 mg/m\^2 intravenously on Day 1 and Day 15 of each 28-day cycle as part of the FOLFIRI treatment regimen. |
| 5-Fluorouracil (5-FU) | DRUG | Standard of care 5-FU will be given at a dose of 2400 mg/m\^2 in continuous infusion over 46 hours on Days 1-2 and Days 15-16 of each 28-day cycle as part of the FOLFIRI treatment regimen. |
| CTX-471 | DRUG | CTX-471 will be given intravenously over the course of 30 minutes (-5/+10) on an outpatient basis every 2 weeks of a 28-day cycle. |
INCLUSION CRITERIA 1. 18 years of age or older 2. Histologically or cytologically confirmed unresectable advanced, metastatic, or recurrent biliary tract cancers (including intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, gallbladder cancer, and ampullary carcinoma) 3. Patients mus...
Top 20 of 78 competitors
Tovecimig is an investigational monoclonal antibody being studied for the treatment of colorectal cancer, specifically metastatic colorectal cancer. It is being evaluated in the second-line setting, meaning for patients whose disease has progressed after earlier therapy. It is not approved for any use and remains in clinical development.
Tovecimig is being developed by Compass Therapeutics, Inc., a clinical-stage biopharmaceutical company that trades under the ticker symbol CMPX. Compass Therapeutics is the sponsor of the clinical program evaluating tovecimig in metastatic colorectal cancer.
Tovecimig is in Phase 2 clinical development. The ongoing study is a Phase 2 trial, and the drug is investigational, meaning it has not been approved by the FDA or any other regulatory authority for commercial use.
Tovecimig is being studied in the trial NCT07662031, titled Tovecimig Plus FOLFIRI in Second Line Metastatic Colorectal Cancer. The Phase 2 study is not yet recruiting, is expected to enroll 25 participants, and is being conducted in the United States in adults aged 18 years and older.
The Phase 2 trial NCT07662031 evaluates tovecimig in combination with FOLFIRI chemotherapy in patients with metastatic colorectal cancer in the second-line setting. It is an uncontrolled, open-label study without randomization or blinding, and it plans to enroll 25 participants across sites in the United States.